Guide Management of Nonalcoholic Fatty Liver Disease

July 2022

You’ll see more focus on managing nonalcoholic fatty liver disease (NAFLD)...partly due to new guidelines.

It’s being called a “sleeper epidemic.” About 1 in 4 patients have this steatosis...but most don’t have symptoms.

NAFLD often goes hand in hand with CV risk factors, such as insulin resistance or diabetes...obesity...and dyslipidemia.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote